证券代码：688356 证券简称：键凯科技 公告编号：2025-024 北京键凯科技股份有限公司 关于取消监事会、修订《公司章程》及修订和制定 部分公司治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京键凯科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开 了第三届董事会第十三次会议，审议通过了《关于取消监事会并修订<公司章 程>的议案》和《关于修订和制定部分公司内部管理制度的议案》，现将具体情 况公告如下： 一、取消监事会情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券 交易所科创板股票上市规则》《上市公司章程指引》等法律、法规、规章、规 范性文件最新规定，并结合公司实际情况，公司拟取消监事会，由董事会审计 委员会行使《公司法》规定的监事会职权，《监事会议事规则》相应废止，公 司各项规章制度中涉及监事会、监事的规定不再适用，并对《公司章程》《董 事会审计委员会工作细则》等相关制度作出相应修订。 在公司股东大会审议通过取消监事会事项前，公司第三届监事会仍将严格 ...

键凯科技长期专注于医用药用聚乙二醇材料的产业化及创新应用开发。公司 基于"高纯度聚乙二醇原料研制技术"、"医用药用聚乙二醇活性衍生物研制技 术"、"聚乙二醇医药应用创新技术"等三大核心技术，借力新材料推动生物医 药创新，充分挖掘聚乙二醇材料的附加价值，持续打造更优、更快、更全的泛聚 乙二醇材料平台及技术水平先进、核心技术自主可控、产业化拓展能力强的高质 量发展整体竞争力。聚乙二醇材料方面，公司积极应对市场需求变化，持续开发 各类创新泛聚乙二醇材料，2025 年上半年共完成 44 种新结构衍生物的开发，8 种衍生物产品的工艺优化、改进与放大，86 种分析方法的开发，新完成 3 种材 料在美国食品药品监督管理局（FDA）的 DMF 备案，1 种材料在国家药品监督 管理局药品审评中心（CDE）的药用辅料登记，1 种材料在新加坡卫生科学局（HSA） 的药用辅料登记。聚乙二醇创新应用方面，2025 年上半年，公司自主研发的 3 类医疗器械注射用交联透明质酸钠凝胶项目已取得医疗器械注册证，截至本报告 披露日已获得生产许可证；注射用透明质酸钠复合溶液项目提交注册申请并获国 家药品监督管理局医疗器械技术审评中心正式受理。 未 ...

证券之星消息，8月19日化学制药板块较上一交易日下跌0.66%，上海谊众领跌。当日上证指数报收于 3727.29，下跌0.02%。深证成指报收于11821.63，下跌0.12%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603520 | 司太立 | 12.16 | 10.05% | 22.82万 | | 2.69亿 | | 603811 | 诚意药业 | 16.82 | 10.01% | 31.23万 | | 5.14亿 | | 003020 | 立方制药 | 37.00 | 9.99% | 8.94万 | | 3.23亿 | | 002940 | 昂利康 | 54.86 | 8.63% | 25.65万 | | 13.73亿 | | 300016 | 北陆药业 | 11.26 | 7.44% | 130.35万 | | 14.77亿 | | 600513 | 联环药业 | 29.47 | 6.08% | 61.98万 | | 18.12亿 | ...

陈光宇教授通过"PEG-HA 凝胶的临床研究与派格注射法案例分享"，从临床实践角度验证产品价值。现 场展示的多组面部年轻化治疗案例让嘉宾直观感受到产品魅力。派格注射法能精准改善面部倦容，注射 后静动态表情自然灵动，既契合求美者自然年轻的需求，也为医生提供更精准的治疗工具，进一步丰富 了美学设计的可能。 8月16日， SILKROSE® 丝玫瑰新品发布会在北京盛大举行并圆满落幕。这场聚焦轻医美技术创新的行 业盛会，汇聚了医美专家、学者、主流媒体及跨界嘉宾。中整协新技术新材料分会会长杨蓉娅、同济医 院整形美容外科主任崔海燕、北京键凯科技股份有限公司（以下简称"键凯科技"，股票代码： 688356.SH）董事长赵宣、天津泰达医药健康产业促进局副局长王泳江、键凯科技医美总监王辰、中国 医学科学院整形外科医院原注射美容中心主任陈光宇、华西医院整形烧伤科博士生导师李正勇副主任、 江西省人民医院整形颌面外科主任刘诚、北京首玺丽格医疗美容诊所院长韩胜、北京博瑞娜医疗美容门 诊部院长王博等众多权威专家到场，共同见证国内首款拥有完全自主知识产权的PEG交联透明质酸钠凝 胶的上市里程碑时刻。 核心技术突围：PEG交联成全场焦点 发 ...

8月16日，SILKROSE丝玫瑰新品发布会在北京盛大举行并圆满落幕。这场聚焦轻医美技术创新的行业 盛会，汇聚了医美专家、学者、主流媒体及跨界嘉宾。中整协新技术新材料分会会长杨蓉娅、同济医院 整形美容外科主任崔海燕、北京键凯科技股份有限公司(以下简称"键凯科技"，股票代码：688356.SH) 董事长赵宣、天津泰达医药健康产业促进局副局长王泳江、键凯科技医美总监王辰、中国医学科学院整 形外科医院原注射美容中心主任陈光宇、华西医院整形烧伤科博士生导师李正勇副主任、江西省人民医 院整形颌面外科主任刘诚、北京首玺丽格医疗美容诊所院长韩胜、北京博瑞娜医疗美容门诊部院长王博 等众多权威专家到场，共同见证国内首款拥有完全自主知识产权的PEG交联透明质酸钠凝胶的上市里程 碑时刻。 核心技术突围：PEG交联成全场焦点 发布会上，丝玫瑰的核心技术优势备受瞩目。键凯科技医美事业部总监王辰先生详细解读了PEG交联技 术的创新突破：相较于传统产品，丝玫瑰的PEG交联结构构建了更丰富的三维空间网络，赋予产品良好 的柔弹性，能让静动态表情自然融合，有效避免移位变形问题。 圆桌会落幕后迎来战略合作签约与新品上市两大核心环节。键凯科技与华润 ...

格隆汇7月30日丨键凯科技(688356.SH)在投资者互动平台表示，公司与康希诺生物子公司康希诺（上 海）生物研发有限公司合作开发的基于新型可离子化甾醇脂质（ISL）的三组分脂质纳米颗粒（ISL-3C- LNP）递送系统在安全性提高和细胞免疫应答增强方面有显著效果，并具有组分简化与专利优势，相关 研究已发表在国际权威期刊ACS Applied Materials & Interfaces上。公司下游客户中包括部分小核酸药物 的研发企业，公司基于客户需求为客户提供各类常规或定制化产品。目前公司客户均处在临床前或早期 临床阶段，尚未对公司营业收入产生重大影响。 ...

Core Insights - The report maintains a positive outlook on small molecule drug conjugates (SMDCs) and related companies, highlighting their potential in cancer treatment due to their ability to enhance efficacy while reducing toxicity [1][5][17] - The report emphasizes the clinical advantages of SMDCs, including better tumor penetration, reduced toxicity to normal cells, and easier control over synthesis and costs compared to antibody-drug conjugates (ADCs) [5][11][12] - The report identifies domestic biopharmaceutical companies, particularly Affinivax, as leaders in the SMDC space, showcasing significant advancements in innovative cancer drug development [5][12][17] Industry Overview - The pharmaceutical and biotechnology sector has shown a relative price-to-earnings (P/E) ratio of 51.14 as of July 25, 2025, which is significantly higher than its historical low of 24.38, indicating a premium valuation compared to the broader market [19] - The report notes that the healthcare sector's valuation is 279% higher than the Shanghai Composite Index, reflecting strong investor interest and confidence in the industry [19] - Recent market performance indicates a 1.90% increase in the pharmaceutical and biotechnology sector from July 21 to July 25, 2025, ranking it 16th among 27 sub-industries [26][29] Company Focus - The report suggests monitoring companies involved in the SMDC space, including Affinivax, and those collaborating with them, such as Innovent Biologics and others, which are expected to benefit from the growing interest in innovative cancer therapies [5][17][18] - Specific companies highlighted for their innovative drug development capabilities include Innovent Biologics, Shunyi Pharmaceutical, and others, which are positioned to capitalize on the advancements in SMDC technology [5][18]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Group 1 - The core viewpoint of the article highlights the active performance of the innovative drug sector, with companies like JianKai Technology seeing a rise of over 10% [1] - Abivax, a French gastrointestinal drug developer, experienced a significant surge of 586% in its stock price after announcing positive results from its Phase III trials for its core drug obefazimod targeting moderate to severe active ulcerative colitis [1] - Other companies in the sector, including Nanjing Xinbai, Lianhuan Pharmaceutical, Weichip Bio, Dize Pharmaceutical, Shutaishen, and Kailaiying, also showed upward movement in their stock prices [1]

New Stock Issuance - New stock issued by Dingjia Precision at a price of 11.16 on July 22, 2025[1] - ST Kelly's tender offer period is from July 17 to August 15, 2025[1] - ST Zitian and other companies have also announced new stock issuances[1] Market Alerts - Significant abnormal fluctuations reported for several stocks including Guangshengtang and Huayin Power[1] - Multiple companies have disclosed announcements regarding stock performance and market activities[1] - The report includes links to detailed announcements for various stocks, indicating ongoing market monitoring[1]